We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Pfizer Inc | NYSE:PFE | NYSE | Common Stock |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
0.16 | 0.58% | 27.86 | 27.905 | 27.52 | 27.86 | 60,567,753 | 00:59:06 |
By Will Feuer
The U.S. Food and Drug Administration amended the emergency use authorizations for Moderna Inc.'s and Pfizer Inc.'s updated Covid-19 vaccines to authorize their use on children as young as six months of age.
The new authorization means children between the ages of six months and five years who received the original two-shot Moderna Covid-19 vaccine series can now receive a booster shot of the updated vaccine, which is tailored for defense against the latest strains of the virus.
Children between the ages of six months and four years who have not yet begun the three-dose series of the Pfizer vaccine, which is made with BioNTech SE, or have not yet received the third dose can now get the updated vaccine as the third dose of their series after receiving two shots of the original Pfizer vaccine, the FDA said.
Children between the ages of six months and four years who have already completed the three-shot Pfizer series will not be eligible for a booster dose of an updated bivalent vaccine, the FDA said.
"As this virus has changed, and immunity from previous Covid-19 vaccination wanes, the more people who keep up to date on Covid-19 vaccinations, the more benefit there will be for individuals, families and public health by helping prevent severe illnesses, hospitalizations, and deaths," FDA Commissioner Robert Califf said.
Write to Will Feuer at Will.Feuer@wsj.com
(END) Dow Jones Newswires
December 08, 2022 10:29 ET (15:29 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Pfizer Chart |
1 Month Pfizer Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions